You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Thursday, March 25, 2021
11 am EDT | 8 am PDT | 3 pm GMT



The new NGL COVID-19 Spike Protein Affinity Resin from Repligen binds the SARS CoV-2 Spike Protein receptor binding domain (RBD) to yield exceptional purity in a single chromatography step. Developed in partnership with Navigo Proteins and Purolite Life Sciences, the product meets all expected requirements of a high-performance resin, including very high selectivity, high dynamic binding capacities and caustic stability over multi-cycle use. Design features of the resin and example performance data will be discussed.



Vikas Gupta.jpgVikas Gupta
Vice President, Chromatography

Vikas Gupta joined Repligen in March 2016 as Vice President of Business Development and Strategy.  Prior to joining Repligen, Mr. Gupta worked at GE Life Sciences from 2012 to 2015 in commercial leadership roles managing its Enterprise Solutions & Services business as well as the single-use and filtration portfolio.  Before GE, Mr. Gupta worked at Millipore from 2004 to 2011 in business development and product management roles,  playing an instrumental role in the early growth of its Mobius single-use bioprocessing business.  He is one of the early champions of a risk-based approach in assessing the impact of extractables and leachables, as well as sustainability initiatives for the disposal of disposables. He received his B.S.  in Chemical engineering and an MBA from India, and an M.S. in Finance from Bentley University in Waltham, MA.



Jamie Peyser
Vice President, Research and Development 

Jamie Peyser has worked at Repligen for over 20 years in various scientific roles within the Research and Development department.  Over this period, Jamie has been a key contributor to advancing Protein Affinity Ligand and Resin design, developing and launching several products for Repligen, and partnering with companies.   Early in his career, he developed clinical phase manufacturing strategies for Repligen’s therapeutic pipeline. Prior to joining Repligen, Jamie worked at Biogen in the downstream purification group and earned a B.S. degree in Biology from Northeastern University. Currently, Jamie leads the R&D Biosciences group, supports new product research, and develops applications for the company’s growing portfolio of products.